Get the Stockscreener App
94.81
0.22%
0.21
Pre-market:
95.81
1.00
+1.05%
Blueprint Medicines Corp stock is traded at $94.81, with a volume of 548.77K.
It is up +0.22% in the last 24 hours and up +10.24% over the past month.
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
See More
Previous Close:
$94.60
Open:
$94.16
24h Volume:
548.77K
Relative Volume:
0.91
Market Cap:
$5.94B
Revenue:
$434.41M
Net Income/Loss:
$-128.05M
P/E Ratio:
-10.32
EPS:
-9.19
Net Cash Flow:
$-250.52M
1W Performance:
-2.14%
1M Performance:
+10.24%
6M Performance:
-9.06%
1Y Performance:
+43.91%
1-Day Range:
$92.66
$95.02
1-Week Range:
$88.05
$100.01
52-Week Range:
$64.80
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
Name
Blueprint Medicines Corp
Sector
Industry
Phone
617-374-7580
Address
45 SIDNEY STREET, CAMBRIDGE, MA
Compare BPMC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| BPMC | 94.81 | 5.94B | 434.41M | -128.05M | -250.52M | -9.19 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-21-23 | Reiterated | Needham | Buy |
| Jul-31-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-05-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Jan-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Needham | Buy |
| Nov-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-14-22 | Initiated | Berenberg | Buy |
| Jul-08-22 | Initiated | Oppenheimer | Outperform |
| Jun-27-22 | Initiated | Wells Fargo | Underweight |
| Jun-10-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-01-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-01-22 | Initiated | Citigroup | Neutral |
| Feb-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-25-22 | Upgrade | Stifel | Hold → Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-21 | Resumed | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Hold |
| Nov-02-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-02-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-30-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Equal Weight |
| Mar-17-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Nov-06-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-22-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Sep-12-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-29-19 | Initiated | Piper Jaffray | Neutral |
| Aug-15-19 | Resumed | Raymond James | Mkt Perform |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-23-19 | Resumed | Goldman | Buy |
| Apr-03-19 | Initiated | Morgan Stanley | Overweight |
| Sep-25-18 | Initiated | Leerink Partners | Outperform |
| Dec-11-17 | Reiterated | Goldman | Buy |
View All
Blueprint Medicines Corp Stock (BPMC) Latest News
Blueprint Medicines (LTS:0HOJ) Enterprise Value : $5,746.9 Mil (As of Nov. 20, 2024) - GuruFocus.com
Victory Capital Management Inc. Trims Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines’ (BPMC) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Blueprint Medicines’ (BPMC) Buy Rating Reiterated at HC Wainwright - Defense World
Prime Capital Investment Advisors LLC Sells 6,476 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short Interest - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Given Buy Rating at Needham & Company LLC - MarketBeat
HC Wainwright Reiterates Buy Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
JP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight Recommendation - MSN
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Yahoo Finance
Key Takeaways From Blueprint Medicines Analyst Ratings - Benzinga
Blueprint Medicines (NASDAQ:BPMC) Now Covered by JPMorgan Chase & Co. - MarketBeat
Mastocytosis Treatment Market Forecasted for Major Expansion - openPR
Entropy Technologies LP Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Holdings Raised by US Bancorp DE - MarketBeat
M&G Plc Makes New $9.10 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Upgraded by StockNews.com - MarketBeat
Blueprint Medicines' SWOT analysis: stock soars on Ayvakit success, pipeline potential - Investing.com
Blueprint Medicines discloses CDK2 inhibitors for cancer - BioWorld Online
Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market LandscapeTechnavio - The Malaysian Reserve
Blueprint Medicines (NASDAQ:BPMC) Price Target Lowered to $151.00 at Wells Fargo & Company - Defense World
Q1 Earnings Forecast for BPMC Issued By HC Wainwright - MarketBeat
Emerald Advisers LLC Has $34.77 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Given “Buy” Rating at Needham & Company LLC - Defense World
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report - Yahoo Finance
Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush - MarketBeat
Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales By Investing.com - Investing.com South Africa
Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales - Investing.com
Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call Transcript - Insider Monkey
Blueprint Medicines stock target upgraded, buy rating on Ayvakit sales - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Receives "Buy" Rating from HC Wainwright - MarketBeat
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and Raised Guidance - GuruFocus.com
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ... - Yahoo Finance
Blueprint Medicines Reports Strong Q3 2024 Results - TipRanks
Blueprint Medicines Corp earnings beat by $0.07, revenue topped estimates - Investing.com Australia
Blueprint Medicines shares buoyed by Ayvakit sales beat - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Shares Gap UpHere's Why - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Canada Finance
Blueprint Medicines: Q3 Earnings Snapshot - Marketscreener.com
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire
When Can We Expect A Profit From Blueprint Medicines Corporation (NASDAQ:BPMC)? - Simply Wall St
Assenagon Asset Management S.A. Lowers Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic? - Yahoo Finance UK
UBS Group Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC) - Defense World
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart
Analyst Ratings For Blueprint Medicines - Benzinga
Blueprint Medicines (NASDAQ:BPMC) Receives New Coverage from Analysts at UBS Group - MarketBeat
Blueprint Medicines Corp Stock (BPMC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):